Study on dose-effect relationship and safety of Modified Huangqi Chifeng Decoction with different doses of Astragalus in the treatment of IgA nephroproteinuria
- Conditions
- IgA nephropathy
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. The diagnosis was IgA nephropathy, and the pathologic reports of renal perforation were reported in all cases;
2. No gender limitation, aged 18-70 years;
3. Moderate proteinuria(24-hour urinary protein quantity is between 1.0-2.5g)accompanied or not accompanied by microscopic hematuria;
4. CKD1-2 (GFR>=60ml/min/1.73m2);
5. TCM syndrome differentiation accords with qi deficiency and blood stasis syndrome as well as wind pathogen and heat toxicity;
6. Non-dialysis patients with infection, acidosis, electrolyte disturbance, hypertension and other aggravating factors are effectively controlled and the condition is stable. The BP is between 130-90/80-60mmHg. Potassium is in the normal range;
7. Voluntarily accept this study and sign the informed consent form.
1. Secondary factors leading to proteinuria, such as purpura nephritis, lupus nephritis;
2. Patients who have been treated by glucocorticoid, immunosuppressant, tripterygium wilfordii preparation in three months are not included;
3. Having mental illness, infectious disease or lactation, pregnancy or planned pregnancy during the study period;
4. Patients complicated with serious diseases of the heart, brain, liver and hematopoietic system, or other serious diseases affecting their survival;
5. Patients with unilateral or bilateral renal artery stenosis;
6. Participants who are participating in other interventional clinical trials.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rine protein quantitation for 24 hours;
- Secondary Outcome Measures
Name Time Method Routine urine;TCM symptom score;Blood fat;renal function;